The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

Living with Chronic Spontaneous Urticaria can be challenging, especially when triggers seem ubiquitous. Here's what you need ...

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years ... spontaneous urticaria experience sudden, unpredictable hives ...